Navigation Links
Onyx Pharmaceuticals Submits New Drug Application for Carfilzomib in Relapsed and Refractory Multiple Myeloma
Date:9/28/2011

by our partner Ono Pharmaceutical Co., Ltd evaluating carfilzomib in Japanese patients with relapsed/refractory multiple myeloma.
  • An expanded access program launched in partnership with the Multiple Myeloma Research Foundation for eligible patients in the U.S. with relapsed and refractory multiple myeloma for whom no satisfactory treatment alternatives are available.

  • About Multiple Myeloma

    Multiple myeloma is the second most common hematologic cancer and results from an abnormality of plasma cells, usually in the bone marrow. In the United States, more than 50,000 people are living with multiple myeloma and approximately 20,000 new cases are diagnosed annually.(ii) Worldwide, more than 180,000 people are living with multiple myeloma and approximately 86,000 new cases are diagnosed annually.(iii)

    About Onyx Pharmaceuticals, Inc.

    Based in South San Francisco, California, Onyx Pharmaceuticals, Inc. is a global biopharmaceutical company engaged in the development and commercialization of innovative therapies for improving the lives of people with cancer and other serious diseases. The company is focused on developing novel medicines that target key molecular pathways. For more information about Onyx, visit the company's website at www.onyx-pharm.com.

    Forward Looking Statements

    This news release contains "forward-looking statements" of Onyx within the meaning of the federal securities laws.  These forward-looking statements include without limitation, statements regarding the progress and results of the clinical development, the expanded access program, safety, regulatory processes, commercialization efforts or commercial potential of carfilzomib.  These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including risks related to the submission, revie
    '/>"/>

    SOURCE Onyx Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. Valeant Pharmaceuticals Announces Approval Of Colesevelam Hydrochloride In Canada
    2. Ampio Pharmaceuticals Receives Notice of Allowance of its Two Patent Applications on the Combination of Zertane™ with Erectile Dysfunction Drugs in Canada
    3. AcelRx Pharmaceuticals Appoints Mark G. Edwards To Its Board of Directors
    4. Adamas Pharmaceuticals Initiates a Phase 2/3 Clinical Study of ADS-5102 for Parkinsons Disease
    5. Questcor Pharmaceuticals Announces Preliminary Operating Metrics for Third Quarter 2011
    6. Rock Creek Pharmaceuticals Offers International Shipping Options for Anatabloc™
    7. Jazz Pharmaceuticals Appoints Head of Research and Development
    8. Oramed Pharmaceuticals Announces Successful Phase 1 Clinical Trial Results for EnteraBio
    9. Inovio Pharmaceuticals Enters Collaboration With U.S. Dept. of Homeland Security to Assess Foot & Mouth Disease Synthetic Vaccines Potential to Help Ensure Nations Food Supply Safety
    10. Elevation Pharmaceuticals Strengthens Management Team with Appointment of Executives
    11. Valeant Pharmaceuticals Intends to Raise Offer for Afexa Life Sciences Inc. to $0.85 per Share
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/23/2015)... ATLANTA , Jan. 23, 2015 More than a ... a quarter of those with private insurance, filled a prescription ... to a report in this week,s Morbidity and Mortality Weekly ... health care providers to treat moderate to severe pain.  They ...
    (Date:1/23/2015)...  Now available for sale, The Armor1 Ankle Roll Guard is ... sprains by cushioning the ankle from an inversion or ... outside of any shoe type and allows the user ... protection against sprains. With customers in physical therapy, podiatry, ...
    (Date:1/23/2015)... , Jan. 23, 2015  CytoSorbents Corporation (NASDAQ CM: ... CytoSorb® extracorporeal cytokine adsorber to reduce deadly inflammation ... receipt of $385,642, net of transaction costs, in ... Technology Business Tax Certificate Transfer Program sponsored by ...
    Breaking Medicine Technology:Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3The Armor1 Ankle Roll Guard is the New Breakthrough Solution for Ankle Sprain Prevention! 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3
    ... and NUREMBERG, Germany, April 13, 2012 ... of mobile C-arms presents its award-winning product portfolio ... Together with Xograph ( http://www.xograph.com ), its UK ... vascular specialists, interventional radiologists and cardiologists to provide ...
    ... ("Unilife" or "Company") (NASDAQ: UNIS ;  ASX: UNS) announced ... fiscal 2012 third quarter ended March 31, 2012 after market trading ... scheduled a conference call for 4:30 p.m. U.S. EDT on Thursday, ... AM AEST) , to review the Company,s financial results, market ...
    Cached Medicine Technology:CX 2012: Elevating the Boundaries of Interventional Imaging with Mobile C-arms 2Unilife Corporation to Announce Financial Results for Fiscal 2012 Third Quarter on Thursday, April 26, 2012 2Unilife Corporation to Announce Financial Results for Fiscal 2012 Third Quarter on Thursday, April 26, 2012 3
    (Date:1/22/2015)... Calif. (PRWEB) January 22, 2015 ... Susan Bonilla (D-Concord) and Kristin Olsen (R-Modesto) were ... their leadership in advancing biotechnology, biomedical science, medical ... and Olsen each received the “2014 Life Sciences ...
    (Date:1/22/2015)... Four years since the release of their debut recording Love ... of Avasa & Matthew Love – the duo are pleased to ... through White Swan Records on February 24, 2015. , THE ROAD ... available to all of us to walk out of the mire ...
    (Date:1/22/2015)... (PRWEB) January 22, 2015 As interest in ... health care gains momentum worldwide, Rev. Eric J. Hall ... Chaplaincy Network (HCCN), will be the keynote speaker on ... in Israel’s public health system. , The conference, “Hope and ...
    (Date:1/22/2015)... Lower-Auto-Insurance.com has released a new blog post explaining the importance of ... the costs of an auto insurance policy . , Clients ... prices for their vehicle insurance policies. The safety a vehicle offers ... Because of this, drivers should always carry a first aid ...
    (Date:12/26/2014)... The US represents the largest market for CRC across the ... that sales of branded therapies were $2.23 billion. The US ... of the disease, high drug treatment rate, and higher drug ... of CRC therapies over the forecast period will be driven ...
    Breaking Medicine News(10 mins):Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 3Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 4
    ... Nursing (NYUCN) received a two-year, $299,990.00 grant from the ... to research the "Impact of an Internationally Educated Nurse ... Homes." According to the Principal Investigator, Laura Wagner, ... NCSBN,s Patient Safety, Practice (LPN/VN, RN), and International Regulatory ...
    ... cell therapies hold enormous potential to address some of ... However, the inability to target cells to tissues of ... To address this hurdle, researchers at Brigham and Women,s ... incorporate homing receptors onto the surface of cells. This ...
    ... THURSDAY, Oct. 27 (HealthDay News) -- A new study warns ... -- or atherosclerosis -- which can lead to heart disease, ... 84 young women, aged 18 to 35, with no known ... blood pressure, high blood cholesterol or family history of premature ...
    ... Americans need to take action to reduce their risk of ... world dies of a stroke every six seconds and about ... about equivalent to the population of Eugene, Ore. or Savannah, ... Prevention. The agency,s message about stroke prevention comes ahead ...
    ... Nursing (NYUCN) received a two-year, $452,218.00 grant from ... ""Proinflammatory Biomarkers and Post-Breast Cancer Lymphedema." Post-breast ... and multiple distressing symptoms, is caused by injuries ... advances in cancer treatment lengthen survival, LE has ...
    ... more cost effective way to provide anesthesia for patients ... a common, often asymptomatic condition that, if not found ... done by investigators at Wake Forest Baptist Medical Center ... anesthesia care (MAC) is better than general anesthesia for ...
    Cached Medicine News:Health News:Programming cells to home to specific tissues may enable more effective cell-based therapies 2Health News:Many Young Adults Unaware They're Developing Heart Disease 2Health News:U.S. Health Officials Urge Lifestyle Changes to Cut Stroke Risk 2Health News:NYU College of Nursing receives 450 thousand dollar NIH grant to research post-breast cancer lymphedema 2Health News:Less invasive anesthetic methods better for endovascular aneurysm repair 2Health News:Less invasive anesthetic methods better for endovascular aneurysm repair 3
    ... EMU36 is a battery-operated digital EEG stand-alone ... signals for epilepsy and other clinical monitoring ... archives these signals through 32 EEG channels ... is a revolutionary monitoring package. The palm-sized ...
    ... Millennium, the newest entry in the ... experience in epilepsy monitoring with the ... Millennium is a powerful Windows-based digital ... recording and review capabilities that are ...
    ... a dual output, general purpose stimulator ... Applications extend from single cell to ... channels can be operated independently or ... outputs are non-isolated constant voltage positive ...
    ... Features 16 R-3 gold-ball electrodes in ... exposed cortex. Each electrode is in ... ease in positioning. Supporting bone clamp ... 8-foot (2.4 m) braided, Teflon-coated wires ...
    Medicine Products: